The impact of high-dose erythropoietin therapy for chemotherapy-relatedanemia

Objective To observe the impact and adverse reactions of high-dose erythropoietin therapy for chemotherapy-related anemia. Methods 101 cases of anemia after chemotherapy were randomly divided into test group or control group. Test group were treated with high-dose erythropoietin therapy, the specific use for the first 1 day for rhEPO 40 000 U, and in the 3th ,5th ,8th, 10th, 12th, 15th, 17th, 19th day given rhEPO10 000 U,every 12 hours one time,rhEPO total dose of 200 000 U. The control group were treated with conventional doses of erythropoietin law,in particular for Erythropoietin 40 000 U, subcutaneously, one time per week for 6 times,rhEPO total dose of 240 000 U. All patients were observed in 6 weeks, every 2 weeks a second efficacy evaluation. Results The test group after 2 weeks of treatment hemoglobin was significantly higher in the control group after 4 weeks was significantly higher hemoglobin;experimental group of 4,6 weeks hemoglobin values were higher( P ＜ 0. 05 ); trial group of 2,4,6 weeks effective rate was 41.2%, 60. 8% and 84. 3%, higher than 17.0% ,29. 8 % and 51.1% ( P ＜ 0.01 ); in improving the quality of life of patients, the test group is better than the control group( P ＜ 0.05 ). Two groups the rate of blood transfusion requirements and adverse reaction rates no significant difference ( P ＞ 0. 05 ). Conclusion The impact of high-dose erythropoietin therapy for anemia associated with chemotherapy is superior to conventional-dose method, with no significant increase in side reactions. Key words: Erythropoietin;  Chemotherapy;  Anemia